Journal Information
Vol. 32. Issue 3.
Pages 127-131 (March 1996)
Share
Share
Download PDF
More article options
Vol. 32. Issue 3.
Pages 127-131 (March 1996)
Full text access
Análisis de la expresión del antígeno nuclear de proliferación celular (PCNA) en 24 carcinomas primarios de pulmón de células no pequeñas y correlación con la supervivencia
Analysis of proliferating cell nuclear antigen expression in 24 cases of primary non-small cell lung cancer and correlation with survival
Visits
10546
V.M. Castellano1, T. Sotelo, C. Ballestín
Departamento de Anatomía Patológica. Hospital Universitario 12 de Octubre. Madrid
A. López-Encuentra*, G. Varela**
* Servicio de Neumología. Hospital Universitario 12 de Octubre. Madrid
** Servicio de Cirugía Torácica. Hospital Universitario 12 de Octubre. Madrid
This item has received
Article information

El antígeno nuclear de proliferación celular (PCNA) o ciclina es una proteína nuclear de 36 kD que está involucrada en la replicación del ADN celular y es considerada como un índice de proliferación en algunas neoplasias. Este trabajo analiza la expresión de PCNA en 24 carcinomas primarios de pulmón de células no pequeñas empleando el anticuerpo monoclonal PC-10 en material procesado en parafina. Encontramos importantes variaciones inter e intratumorales en la expresión de PCNA. No observamos relación estadísticamente significativa entre la cantidad de PCNA expresada y el tamaño y localización tumoral, índice mitósico, tipo histológico del tumor y edad del paciente. Estudiamos la supervivencia en los pacientes en 19 casos con el propósito de correlacionarla con la expresión de PCNA, obteniendo una relación estadísticamente significativa (r=0,47; p < 0,05) entre la cantidad de PCNA expresada y la supervivencia en los casos incluidos en nuestro estudio, pero al establecer un sistema de graduación de la expresión de PCNA en tres grados -leve (0-25%), moderado (25-50%) e intenso (> 50%)- no encontramos diferencias estadísticamente significativas entre las supervivencias ni un valor pronóstico en la graduación de PCNA.

Palabras clave:
Cáncer de pulmón
Antígeno nuclear de proliferación celular (PCNA)
Ciclina
Supervivencia
Factor pronóstico
Immunohistoquímica

Proliferating cell nuclear antigen (PCNA) is a 36kD nuclear protein involved in DNA replication that is believed to provide an indication of proliferation in some neoplasms. This study analyzes PCNA expression in 24 cases of primary non-small cell lung cancer using monoclonal PC-10 antibodies in paraffin embedded material. We found significant inter and intra-tumoral variations in PCNA expression, and no statistically significant relation between the amount of PCNA expression and the size and location of tumors, index of mitosis, histological tumor type or patient age. We found a statistically significant relation (r=0.47; p < 0.05) between survival and amount of PCNA expression in a sample of 19 cases, but no statistically significant differences in survival related to whether PCNA expression was slight (0-25), moderate (25%-50%) or high (> 50%), and no prognostic value for degree of PCNA expression.

Key words:
Lung cancer
Proliferating cell nuclear antigen
PCNA
Cyclin
Survival
Prognostic factor
Immunohistochemistry
Full text is only aviable in PDF
Bibliografía
[1.]
K. Miyachi, M.J. Frilzlcr, E.M. Tan.
An auloantibody to a nuclear antigen in proliferating cells.
J Immunol, 121 (1978), pp. 2.228-2.234
[2.]
R. Bravo, J.E. Celis.
A search for differential polypeptide synthesis throughout the cell cycle of Hela cells.
J Cell Biol, 84 (1980), pp. 795-802
[3.]
M.B. Mathews, R.M. Bernstein, B.R. Franza, J.I. Garrels.
The identity of the proliferating cell nuclear antigen and cvclin.
Nature, 309 (1984), pp. 374-376
[4.]
Y. Takasaki, D. Fischwild, E.M. Tan.
Characterization of proliferating cell nuclear antigen recognized hy autoantibodies in lupus sera.
J Exp Med, 159 (1984), pp. 981-992
[5.]
J.E. Celis, A. Celis.
Cell cycle dependent variations in the distribution of the nuclear antigen in cultured celis: subdivision of S phase.
Proc Natl Acad Sci USA, 82 (1985), pp. 143-157
[6.]
D. Jaskulski, J.K. De Riel, W.E. Mercer, B. Calabretta, R. Baserga.
(Inhibition of cellular proliferation by antisence oligodeoxynucleotides to PC NA cyclin.
Science, 240 (1988), pp. 1.544-1.546
[7.]
M. Zuber, E.M. Tan, M. Ryoji.
Involvement of proliferating cell nuclear antigen (cvclin) in DNA replication in living cells.
Mol Cell Biol, 9 (1989), pp. 57-66
[8.]
C.K. Tan, C. Castillo, A.G. So, K.M. Downey.
An auxiliary protein for DNA polymerase-delta from foetal calf thymus.
J Biol Chem, 261 (1986), pp. 12.310-12.316
[9.]
R. Bravo, R. Fratik, P.A. Blundell, H. MacDonald-Bravo.
Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.
Nature, 326 (1987), pp. 515-517
[10.]
G. Prelich, C.K. Tan, M. Kostura, M.B. Mathews, Ag. So, K.M. Downey, B. Stillman.
Functional identity of proliferaiing cell nuclear antigen and a DNA polymerase-delta auxilliary protein.
Nature, 326 (1987), pp. 517-520
[11.]
B.A. Robbins, D. De la Vega, K. Ogata, E.M. Tan, R. Nakamura.
lmmunohistochemical detection of proliferating cell nuclear antigen in solid human malignances.
Arch Pathol Lab Med, 111 (1987), pp. 841-845
[12.]
P.A. Hall, D.A. Levison, A.L. Woods, C.C.W. Yu, D.B. Kelloek, J.A. Watkins, D.M. Bames, C.E. Gillet, R. Camplejohn, R. Dorel, N.H. Waseen, D.P. Lane.
Proliferaiing cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.
J Pathol, 162 (1990), pp. 285-294
[13.]
P.H.M.H. Theunissen, M.P.G. Leers, E.C.M. Bollen.
Proliferating cell nuclear antigen (PCNA) expresion in formalin-fixed tissue of non-small cell lung carcinoma.
Hislopathology, 20 (1992), pp. 251-255
[14.]
F.A. Carey, G. Fabbroni, D. Lamb.
Expression of proliferating cell nuclear antigen in lung cancer: a systematic study and correlation with DNA ploidy.
Hislopathology, 20 (1992), pp. 499-503
[15.]
G. Fontanini, P. Macchiarini, S. Pepe, A. Ruggiero, M.J. Hardin, D. Bigini, S. Vignati, R. Pingitore, C.A. Ageletti.
The expression of proliferating cell nuclear antigen in paraffin sections of peripheral. node-negative non-small cell lung cancer.
Cancer, 70 (1992), pp. 1.520-1.527
[16.]
Macchiarini P, Fontanini G, Hardin MJ. Chuanchich H. Bigini D. Vignati S. Pingitore R. Angcletti A. Blood vessel invasion by tumor cells predicts recurrence in completely resected TI N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 199; 106: 80-89.
[17.]
J.I. Ogawa, T. Tsurumi, S. Yamada, S. Koide, A. Shohtsu.
Blood vessel invasion and expression of sialyl Lewis and proliferating cell nuclear antigen in stage I non-small cell lung cancer.
Cancer, 73 (1994), pp. 1.177-1.183
[18.]
J.I. Ogawa, M. Iwazaki, H. Inoue, S. Koide, A. Shohtsu.
Immunohistochemical study of glutatione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivitv.
Cancer, 71 (1993), pp. 2.204-2.209
[19.]
R.L. García, M.D. Coltrera, A.M. Gown.
Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fi.xed, embedded tissues.
Ani J Pathol, 134 (1989), pp. 733-739
[20.]
M. Fujii, M. Motoi, H. Saeki, K. Aoe, S. Moriwaki.
Prognoslic significance of proliferating cell nuclear antigen (PCNA) expression in non-small cell lung cancer.
Acta Med Okayama, 4 (1993), pp. 103-108
[21.]
M. Ebina, S.M. Sleinberg, J.L. Mulshine, R.I. Linnoila.
Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.
Cancer Res, 54 (1994), pp. 2.496-2.503
[22.]
T. Ishida, S. Kaneko, K. Akazawa, M. Tateishi, K. Sugio, K. Sugimachi.
Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients.
Cancer Res, 53 (1993), pp. 5.000-5.003
[23.]
G. Fontanini, S. Vignati, D. Bigini, G.R. Merlo, A. Rihccchini, C.A. Angeletti, et al.
Human non-small cell lung cancer: p53 protein acumulation is an carly event and persists during metastatic progression.
J Pathol, 174 (1994), pp. 23-31
[24.]
T. Kawai, M. Suzuki, S. Kono, N. Shinomiya, M. Rokutanda, K. Tagaki, et al.
Proliferating cell nuclear aniigen and Ki-67 in lung carcinoma. Correlation wilh DNA flow cytometric analysis.
Cancer, 74 (1994), pp. 2.468-2.473
[25.]
R. Bravo, H. MacDonald-Bravo.
Existence of two populalions of cyclin/proliferating cell nuclear antigen during the cell cyle: association with DNA replication siles.
J Cell Biol, 108 (1987), pp. 1.549-1.854
[26.]
C.D. Chang, L. Ottavio, S. Travalli, Ke. Lipson, R. Baserga.
Transcriplional and posttranscriptional regulation of mRNA levels of the proliferating cell nuclear antigen gene.
Mol Cell Biol, 10 (1990), pp. 3.289-3.296
[27.]
J.M. Almendral, D. Huebsch, P.A. Blundell, H. MacDonald-Bravo, R. Bravo.
Cloning and sequence of the human nuclear protein cyclin: homology with DNA binding proteins.
Proc Natl Acad Sci USA, 84 (1987), pp. 1.575-1.579
[28.]
N.H. Waseem, D.P. Lane.
Monoclonal antibody analysis of the pro liferating cell nuclear antigen (PCNA). Struclural conservation and the delection of a nucleolar form.
J Cell Sci, 96 (1990), pp. 121-129
[29.]
K. Ogata, P. Kurki, J.E. Celis, R.M. Nakamura, E.M. Tan.
Monoclonal antibodies to a nuclear protein (PCNA/cyclin) associated with DNA replication.
Exp Cell Res, 168 (1987), pp. 475-486
[30.]
A.L. Woods, P.A. Hall, N.A. Shepherd, A.M. Handy, N.H. Weseem, D.P. Lane, et al.
The assessment of proliferating cell nuclear antigen (PCNA) iminunostaning in primare gastrointestinal lymphomas and its relationship to histological grade. S+G2+M phase fraction flow cylometric analysis) and prognosis.
Histopathology, 19 (1991), pp. 21-27
[31.]
C.C.W. Yu, P.A. Hall, C.D.M. Fletcher, R.S. Camplejohn, N.H. Weseem, D.P. Lane, et al.
Haemangiopericytoma: the prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA).
Histopathology, 19 (1991),
Copyright © 1996. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?